Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
ICHIRO IEIRI Last modified date:2018.05.23



Undergraduate School
Administration Post
Dean of the Faculty of Pharmaceutical Sciences
Other
Other


E-Mail
Homepage
http://pedu.phar.kyushu-u.ac.jp/
Introduction of Clinical Pharmacy Education Center .
http://doutai.phar.kyushu-u.ac.jp/
Introduction of Department of Clinical Pharmacokinetics. .
Fax
092-642-6660
Academic Degree
Pharmaceutical Sciences
Field of Specialization
Clinical Pharmacokinetics, Pharmacogenomics/Pharmacogenetics, Clinical Pharmacy
Outline Activities
My main research theme is describing large inter-invidiual differences in the pharmacodynamics and pharmacokinetics of clinically useful drugs from the standing points of genetic polymorphisms and gene expression mechanisms.
Another major issue is an application of pharmacometircs to individualized drug therapy.
My lecture titles are pharmacokinetics and clinical pharmacy.
Councils of some scientific societies
Editors of some international and domedtic journals
My social activities include tye director of softball team in a junior school.
Research
Research Interests
  • Application of metabolome analysis to pharmacoenomic research area.
    keyword : pharmacogenomics, biomarkers, metabolome analyais
    2015.04~2020.05.
  • Meta analysis combined with pharmacometrics
    keyword : Population pk/pd - meta analysis
    2015.04~2016.05.
  • Ethnic differency of pharmacokinetics in Asis
    keyword : Asia, Pharmacokinetics, ethnicity
    2012.05~2016.05.
  • Pharmacodynamic analysis by pharmacometrics using in-hospital medication information
    keyword : Population pk/pd analysis
    2012.06~2016.05.
  • Plasma miRNA concentration as a biomarker for drug transporters
    keyword : Transporter
    2012.06~2016.05.
  • Transporter in vivo functions
    keyword : Transporter
    2011.06~2016.05.
  • Establishment of analytical methofs for drugs in human materials
    keyword : drugs, analytical methods, establishment
    2011.04~2016.05.
  • Useful biomarkers for appropriate drug use.
    keyword : appropriate drug use, biomarkers
    2010.04~2016.05.
  • Microdosing clinical study
    keyword : Microdosingね clinical study
    2009.04.
  • Role of miRNAs for expression of pharmacokinetic/pharmacodynamic genes.
    keyword : miRNA, PK/PD, gene expression
    2008.04~2016.05.
  • Epigenetic mechanisms for expression of pharmacokinetic/pharmacodynamic genes.
    keyword : methylation, imprinting, histone, CYP3A4
    2007.04~2016.05.
  • Epigenetic mechanisms for expression of pharmacokinetic/pharmacodynamic genes.
    keyword : methylation, imprinting, histone
    2007.04~2015.05.
  • Population pharmacokinetics
    keyword : population pharmacokinetic pharmacodynamic analysis
    2005.12.
  • Investigation for Pharmacogenetics/pharmacogenomics (PGx)
    keyword : Pharmacogenetics、pharmacogenomics
    1996.07.
Current and Past Project
  • Applcation of microdosing tests for drug developemental ascenes based on PK/PD/PGx theories.
  • Developement of programs for growing leaders of clinical pharmacists.
  • To accelerate (or developmental support) seeds from individual reseachers in Kyushu University to appropriate clinical situations.
  • Applcation of microdosing tests for PK/PD/PGx scenes.
Academic Activities
Books
1. 家入 一郎, Pharmacogenomics of drug transporters: clinical implications, The Royal Society of Chemistry, RSC Drug Discovery Series No.55, 2016.05.
Reports
1. 家入 一郎, Drug-drug interactions that interfere with statin metabolism., Expert Opin Drug Metab Toxicol., 2015.11.
2. 家入 一郎, Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions., Pharmacogenomics, 2014.01.
3. 家入 一郎, Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs, Drug Metab Pharmacokinet, 2013.01.
4. ICHIRO IEIRI, Y. Akamine, Psychotropic drug-drug interactions involving P-glycoprotein., CNS Drugs, 2012.11.
5. Ichiro Ieiri, Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)., Drug Metab Pharmacokinet. 2012;27(1):85-105, 2012.03.
6. Ieiri I, Higuchi S, Sugiyama Y, Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs., Expert Opin Drug Metab Toxicol., 5(7):703-29. , 2009.06.
Papers
1. 家入 一郎, Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer., Cancer Chemother Pharmacol. , 78, 5, 1013-1023, 2016.11.
2. 家入 一郎, Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines., Sci Rep. , 6, 32299, 2016.08.
3. 家入 一郎, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol., 80, 5, 1236-1237, 2015.11.
4. 家入 一郎, Neonatal Dubin-Johnson syndrome: novel compound heterozygous mutation in the ABCC2 gene., Pediatr Int., 56, 5, e62-e64, 2014.10.
5. 家入 一郎, Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers., J Clin Pharm Ther. , 40, 1, 98-103, 2014.09.
6. 家入 一郎, Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment., Pharmacogenet Genomics, 2014.07.
7. 家入 一郎, Identification and functional characterization of novel nonsynonymous variants in the human multidrug and toxin extrusion 2-k., Drug Metab Dispos, 42, 9, 1432-1437, 2014.09.
8. 家入 一郎, Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers., Eur J Clin Pharmacol, 70, 9, 1087-1095, 2014.09.
9. 家入 一郎, Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records., Br J Clin Pharmacol, 2014.04.
10. 家入 一郎, Influences of artificial heart-lung machine operation on the binding sites of albumin: possibility of an effective administration plan., Int J Artif Organs, 37, 2, 99-108, 2014.02.
11. 家入 一郎, Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis., J Clin Pharmacol, 54, 8, 937-948, 2014.08.
12. 家入 一郎, Mechanism of the 24-hour rhythm of tumor necrosis factor-alpha formed by onset of rheumatoid arthritis., Chronobiol Int., 31, 4, 564-571, 2014.05.
13. 家入 一郎, Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions., Pharmacogenomics., 14, 4, 1745-1764, 2013.11.
14. 家入 一郎, Association between DNA methylation in the miR-328 5'-flanking region and inter-individual differences in miR-328 and BCRP expression in human placenta., PLoS One. , 21, 8, e72906, 2013.08.
15. 家入 一郎, MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells., BMC Cancer, 13, 1, 369, 2013.08.
16. 家入 一郎, MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells., BMC Cancer, 13, 1, 369, 2013.08.
17. 家入 一郎, Direct and rapid genotyping of SLCO1B1 388A>G and 521T>C in human blood specimens using the SmartAmp-2 method., AAPS J, 15, 2, 618-622, 2013.03.
18. 家入 一郎, Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs., J Clin Pharmacol, 53, 6, 654-661, 2013.06.
19. 家入 一郎, Role of Methotrexate Polyglutamation and Reduced Folate Carrier 1 (RFC1) Gene Polymorphisms in Clinical Assessment Indexes., Drug Metab Pharmacokinet, 28, 5, 442-445, 2013.10.
20. ICHIRO IEIRI, M. Fukaw, K. Maeda, Y. Suguyama, Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing., Int J Clin Pharmacol Ther., 10.5414/CP201763., 50, 10, 689-700, 2012.10.
21. ICHIRO IEIRI, K. Sonoki, M. Iwase, S. Ohdo, Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity., J Cardiovasc Pharmacol., 10.1097/FJC.0b013e3182646ccc., 60, 4, 367-374, 2012.10.
22. ICHIRO IEIRI, S. Endo, A. Fukuhori, S. Tokuhiro, Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure., J Hum Genet., 10.1038/jhg.2012.63. , 57, 8, 531-544, 2012.08.
23. ICHIRO IEIRI, H. Jeon, IJ. Jang, KS. Lin, Apple juice greatly reduces systemic exposure to atenolol., Br J Clin Pharmacol. , 10.1111/j.1365-2125.2012.04324.x., 75, 1, 172-179, 2013.01.
24. ICHIRO IEIRI, K.Kato, H.Kusuhara, Y. Sugiyama, Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals., Pharmacogenet Genomics., 10.1097/FPC.0b013e3283517012., 22, 5, 344-354, 2012.05.
25. ICHIRO IEIRI, Y. Date, Y. Nishibatake, Takeshi Hirota, Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues., Lung Cancer, 10.1016/j.lungcan.2011.12.018. , 166, 6, 1793-1803, 2012.07.
26. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y., Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP., Br J Pharmacol., 10.1111/j.1476-5381.2012.01887.x., 2012.02.
27. Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER., Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease., Clin Neuropharmacol., 35, 1, 25-9, 2012.02.
28. Egashira K, Sasaki H, Higuchi S, Ieiri I., Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats., Drug Metab Pharmacokinet., 27, 2, 242-7, 2012.04.
29. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, Noguchi T, Yoshida K, Sugiyama Y., Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose., Pharmacogenet Genomics. , 2011 Aug;21(8):495-505, 2011.08.
30. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, Chiyoda T, Miyagawa M, Irie S, Iwasaki K, Sugiyama Y., Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose., J Clin Pharmacol., in press, 2011.05.
31. Saito J, Hirota T, Kikunaga N, Otsubo K, Ieiri I., Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: Relationship to epigenetic variations in the 5'-upstream regulatory region., J Pharm Sci. , 2011 Sep;100(9):3875-83., 2011.09.
32. Sasaki T, Hirota T, Ryokai Y, Kobayashi D, Kimura M, Irie S, Higuchi S, Ieiri I., Systematic screening of human ABCC3 polymorphisms and their effects on MRP3 expression and function., Drug Metab Pharmacokinet., in press, 2011.04.
33. Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, Horii T, Otsubo K, Ieiri I., Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients., Antimicrob Agents Chemother. , 2011 May;55(5):1867-73., 2011.05.
34. Ide T, Sasaki T, Maeda K, Higuchi S, Sugiyama Y, Ieiri I., Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information on SLCO1B1 and ABCC2 Polymorphisms., J Clin Pharmacol. , 49(11):1309-17

, 2009.11.
35. Sasaki T, Tabuchi H, Higuchi S, Ieiri I., Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting., Pharmacogenomics. , 10(8):1257-66, 2009.08.
36. Ieiri I, Higuchi S, Sugiyama Y., Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs., Expert Opin Drug Metab Toxicol. , 5(7):703-29, 2009.05.
37. Kodama A, To H, Kinoshita T, Ieiri I, Higuchi S., Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice., J Pharm Pharmacol. , 61(5):615-21, 2009.05.
38. Sugahara H, Maebara C, Ohtani H, Handa M, Ando K, Mine K, Kubo C, Ieiri I, Sawada Y. , Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease., Eur J Clin Pharmacol., 65(7):699-704. , 2009.06.
39. Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I., Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy., Cancer Chemother Pharmacol., 63(6):1165-9., 2009.05.
40. Suwannakul S, Ieiri I, Kimura M, Kawabata K, Kusuhara H, Hirota T, Irie S, Sugiyama Y, Higuchi S., Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism., J Hum Genet., 53(10):899-904., 2008.06.
41. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, Higuchi S, Sugiyama Y., Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther. , 84(1):95-103., 2008.06.
42. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I., Polymorphism in human organic cation transporters and metformin action., Pharmacogenomics., 9(4):415-22., 2008.04.
43. Hirota T, Takane H, Higuchi S, Ieiri I., Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters; DNA methylation and other mechanisms., Curr Drug Metab., 9(1):34-8., 2008.01.
44. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y., SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers., Clin Pharmacol Ther. , in press, 2007.04.
45. Shikata E, Yamamoto R, Takane H, Shigemasa C, Ikeda T, Otsubo K, Ieiri I., Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin., J Hum Genet. , 52(2):117-22, 2007.02.
46. Shikata E., Ieiri I., Ishiguro S., Takane H., Ohgi S. and Otsubo K., Multiple gene polymorphisms and warfarin sensitivity., Eur J Clin Pharmacol, 62(10):881-3, 2006.10.
47. Takane H., Miyata M., Burioka N., Shigemasa C., Shimizu E., Otsubo K. and Ieiri I., Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy., J Hum Genet, 51; 822-826, 2006.06.
48. Maeda K., Ieiri I., Yasuda K., Fujino A., Fujiwara H., Otsubo K., Hirano M., Watanabe T., Kitamura Y., Kusuhara H. and Sugiyama Y., Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril., Clin Pharmacol Ther, 79; 427-439, 2006.05.
49. Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I., Rifampin reduces the analgesic effect of transdermal fentanyl.
, Ann Pharmacother. , 39: 2139-40, 2005.12.
50. Ieiri I., Kimura M., Irie S., Urae A., Otsubo K. and Ishizaki T., Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status., Pharmacogenetics and Genomics, 15; 851-859, 2005.12.
Presentations
1. 家入 一郎, Value and limitations of cutting-edge science (e.g., gene therapy and pharmacogenomics ) to patient care here and now
, FIP's World Congress of Pharmacy and Pharmaceutical Sciences, 2015.09.
2. I will present candidate multiple gene analysis for prediction of individual warfarin response..
Educational
Educational Activities
My education activities include "Clinical Pharmacokinetics" for 3rd degree students, "Clinical Pharmacy Practice" for 4th degree students, "Pharmacokinetics" for graduate school students.
Social
Professional and Outreach Activities
Coach for base ball team in a area of junior shcool..